title: The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling.
abstract: We have shown that vitronectin (Vn) binding to a cysteine loop sequence within the extracellular domain of the beta3-subunit (amino acids 177-184) of alphaVbeta3 is required for the positive effects of Vn on IGF-I signaling. When Vn binding to this sequence is blocked, IGF-I signaling in smooth muscle cells is impaired. Because this binding site is distinct from the site on beta3 to which the Arg-Gly-Asp sequence of extracellular matrix ligands bind (amino acids 107-171), we hypothesized that the region of Vn that binds to the cysteine loop on beta3 is distinct from the region that contains the Arg-Gly-Asp sequence. The results presented in this study demonstrate that this heparin binding domain (HBD) is the region of Vn that binds to the cysteine loop region of beta3 and that this region is sufficient to mediate the positive effects of Vn on IGF-I signaling. We provide evidence that binding of the HBD of Vn to alphaVbeta3 has direct effects on the activation state of beta3 as measured by beta3 phosphorylation. The increase in beta3 phosphorylation associated with exposure of cells to this HBD is associated with enhanced phosphorylation of the adaptor protein Src homology 2 domain-containing transforming protein C and enhanced activation MAPK, a downstream mediator of IGF-I signaling. We conclude that the interaction of the HBD of Vn binding to the cysteine loop sequence of beta3 is necessary and sufficient for the positive effects of Vn on IGF-I-mediated effects in smooth muscle cells.
authors.affiliation: Division of Endocrinology, University of North Carolina, Chapel Hill, North Carolina 27599-7170, USA. laura_maile@med.unc.edu
authors.forename: Laura A
authors.initials: LA
authors.lastname: Maile
authors.forename: Walker H
authors.initials: WH
authors.lastname: Busby
authors.forename: Kevin
authors.initials: K
authors.lastname: Sitko
authors.forename: Byron E
authors.initials: BE
authors.lastname: Capps
authors.forename: Tiffany
authors.initials: T
authors.lastname: Sergent
authors.forename: Jane
authors.initials: J
authors.lastname: Badley-Clarke
authors.forename: Yan
authors.initials: Y
authors.lastname: Ling
authors.forename: David R
authors.initials: DR
authors.lastname: Clemmons
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D004247:DNA / Q000235:genetics; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008969:Molecular Sequence Data; D009130:Muscle, Smooth / Q000378:metabolism; D010766:Phosphorylation; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013552:Swine; D019096:Vitronectin / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
chemical_list: D011994:Recombinant Proteins; D019096:Vitronectin; D007334:Insulin-Like Growth Factor I; D006493:Heparin; D004247:DNA